cyrilzakka/clinical-trials huggingface dataset:
Effects of Windlass Versus Calcaneal Taping in Football Player With Plantar Fasciitis.

Plantar fasciitis is a prevalent ailment that affects the plantar fascia, a dense tissue strip that spans the underside of the foot, from the heel bone to the toes. Football players are especially susceptible to this ailment because of the sport's high-impact nature, which includes repetitive sprinting, jumping, and quick changes in direction. Taping has been used for many years for various ailments. The purpose of this study is to determine the effects of two taping techniques i.e. windlass taping and calcaneal taping on pain, flexibility and lower extremity function in football players.

The study will be a randomized clinical trial conducted at the Pakistan Sports Board and The Raider's football club over a duration of 10 months after synopsis approval. The required sample size for each group, after accounting for a 10% attrition rate, will be 17. Two study groups will be established: Group A, which will receive calcaneal taping among football players, and Group B, which will receive windlass taping among football players. Nonprobability purposive sampling will be employed. Data will be collected using the Numeric Pain Rating Scale (NPRS), Hubscher maneuver, goniometer, and lower extremity functional scale (LEFS) to assess pain severity, flat foot type flexibility, joint range of motion, and lower limb function, respectively. This comprehensive study aims to contribute valuable insights into the effects of calcaneal and windlass taping on football players.

Eligibility Criteria:
Inclusion Criteria:

* positive windlass test
* Pain can appear after a period of intense training, normally declines with the warm up and reappears at the end of training.
* Intense and acute heel pain localized primarily where plantar fascia attaches to the anterior calcaneus.
* The pain presents on first walking in the morning or after a rest period.

Exclusion Criteria:

* Congenital deformity of ankle and foot.
* History of foot and ankle fracture.
* History of ankle and foot surgery.
* Previous surgery or treatment for plantar fasciitis in the previous 6 months.
* Use of an assistive device for ambulation
* Use of an assistive device for ambulation
* Refuse to participate in the study
Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer

The study aims to evaluate the ability of representative vacuum-assisted minimal invasive biopsy (VAB) to diagnose pathological complete response (pCR=ypT0) in breast cancer patients after neoadjuvant chemotherapy (NACT).

Neoadjuvant chemotherapy (NACT) is an increasingly used approach for patients with locally advanced and primarily inoperable breast cancer or for patients with potentially chemosensitive tumors. In clinical routine surgical treatment follows the pre-operative chemotherapy. However, recent studies have demonstrated that shrinking tumors need less surgical treatment indicating that patients with pCR could potentially be spared of surgery in the future.

Up to now, prediction of pCR after NACT, i.e. diagnosing a pCR without surgery, is based on tumor biology at diagnosis, the applied NACT regimen and breast imaging results; all with mediocre accuracy. This prospective, monocenter diagnostic trial aims to explore if minimal invasive biopsies (MIB) might overcome this diagnostic challenge.

From September 1st, 2014 to February 15th, 2015 the investigators performed ultrasound guided vacuum-assisted minimal invasive biopsy (VAB) on 50 breast cancer patients after NACT and directly prior to surgery. To analyse VAB pathologically results were categorized as follows: residual vital tumor cells (invasive, in situ, both, lymphangiosis carcinomatosous) present, (significant parts of) the tumor bed present, neither vital tumor cells nor (significant parts of) the tumor bed (indicating a non representative VAB). The results were compared to those of the pathological examination of surgical specimen.

Eligibility Criteria:
Inclusion Criteria:

The investigators included patients

* after neoadjuvant chemotherapy (NACT) according to the NACT protocol
* with at least one detectable mass / marker after NACT in ultrasound
* with cT1c-cT4a-c tumors
* after informed consent
* with unilateral or bilateral primary breast cancer, confirmed histologically prior to chemotherapy
* with known grading, ER/PgR/HER-2neu- and Ki-67 status
* with breast ultrasound, mammography (and breast MRI where necessary) before and after NACT
* clinical / imaging partial or complete response to NACT

Exclusion Criteria:

The investigators excluded patients from the study with

* NACT \<12 weeks because of termination due to progressive disease, massive adverse events or patient wish
* non-detectable mass in ultrasound / dislocation of marker (\> 10mm distance to the initial lesion)
* cT4d stage (inflammatory breast cancer)
* M1 stages
* stable disease according to a multimodal assessment of ultrasound, mammography and breast MRI (if available) according to RECIST
Prevention of Ulnar Collateral Ligament (UCL) Injuries in Minor League Pitchers

This is a study of the muscle stabilizers of the elbow with respect to the prevention of Ulnar Collateral Ligament (UCL) injuries in pitchers. Pitchers are assessed at spring training and end of season for approximately 5 years. Pronator, flexor digitoum superficialis (FDS), and wrist flexion strength will be measured and correlated with upper extremity injuries and time missed from pitching. The investigators will also be measuring loss of strength over the season. The goal is to learn whether strength in these muscles prevents UCL injuries and finally whether these muscles can be strengthened to avoid such injuries.

The goal of this study is to assess whether the strengths of the secondary muscular stabilizers toward valgus stress at the elbow, the wrist flexors, flexor digitorum superficialis, and pronator teres emanating from the medial epicondyle, affect the incidence of ulnar collateral ligament injuries of the elbows in pitchers. Pitchers in the minor leagues of a single professional baseball club will have the strength of these secondary muscular stabilizers assessed and then correlated to ulnar collateral ligament injuries and time missed from baseball season and subsequent seasons. A secondary goal is to assess whether strengthening exercises targeted toward these muscular stabilizers of the elbow can decrease the incidence of ulnar collateral ligament injuries in young baseball pitchers. This could impact the field by changing the emphasis from reconstruction and rehabilitation of ulnar collateral ligament injuries to prevention.

Eligibility Criteria:
Inclusion Criteria:

* Pitchers that are currently on a minor league baseball team.

Exclusion Criteria:

* Pitchers that currently have upper extremity injuries or are in active rehab for upper extremity injury.
Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment

his clinical trial was conducted to determine the non-inferiority and safety of prophylactic antiviral treatment of Tenofovir alafenamide (TAF) compared to Tenofovir disoproxil fumarate (TDF) in patients with malignant hematological diseases requiring prophylactic hepatitis B antiviral treatment. Confirm.

In the case of TAF, domestic evidence when used as a first-line treatment is insufficient, so in this clinical trial, the virus suppression effect compared to TDF during the first administration of TAF to patients with malignant hematological diseases requiring prophylactic hepatitis B antiviral treatment was investigated. We aim to secure non-inferiority and additionally confirm the safety of TAF's known advantages of reducing renal function damage and protecting bone function.


Eligibility Criteria:
Inclusion Criteria:

1. Adult men and women over 19 years of age and under 65 years of age
2. Patients who meet the following criteria A or B A. Those scheduled for hematopoietic stem cell transplantation and treatment with immunosuppressants or chemotherapy.

   B. Those scheduled to receive anticancer treatment including rituximab
3. HBcAb positive patient
4. Patients who voluntarily agreed to participate in this clinical trial and signed a written consent form

Exclusion Criteria:

1. Patients taking oral chronic hepatitis B antiviral drugs before starting the study
2. Galactose intolerance. Patients with genetic problems such as Lapp lactase deficiency or glucose-galactose malabsorption
3. Patients with hypersensitivity to tenofovir alafenamide citrate or tenofovir disoproxil orotate
4. Patients with abnormal renal function (e-GFR less than 15mL/min) or end-stage renal disease requiring dialysis
5. Hepatitis C patients
6. HIV-infected patients
7. Pregnant women, lactating women, or patients planning to become pregnant
8. If you are participating in another clinical trial administering medication
9. Patients who do not agree to participate in this clinical trial
10. Adults with impaired consent capacity who are unable to give consent on their own
11. Those who have taken other clinical trial drugs for less than 24 weeks
12. Other clinically determined by the principal investigator to be difficult for the clinical trial subject to conduct the clinical trial.
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy

This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in 1st line (cohort 2) or ≥2nd line (cohort 1) for the first time, and are treated within the market authorization approval. Participants are to be enrolled into the study no earlier than the decision to initiate treatment with nivolumab and no later than the first dose of nivolumab treatment.


Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

- Adult participants (at least 18 years of age at time of treatment decision)

* Diagnosis of Squamous cell carcinoma of the head and neck (SCCHN) and participants are progressing on or after platinum-based therapy, administered for locally advanced, metastatic or recurrent disease (Cohort 2: prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting, e.g. radiotherapy)
* Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease)
* Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in Germany) has already been taken

Exclusion Criteria:

* Current primary diagnosis of a cancer other than SCCHN, ie, a cancer other than SCCHN or cancer of unknown primary (CUP-syndrome) that requires systemic or other treatment, or has not been treated curatively (as per discretion of the investigator)
* Previously treated with nivolumab and/or ipilimumab, an anti-PD-1, anti-programmed death ligand 1 (anti-PD-L1), anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (applicable for any indication)
* Currently included in an interventional clinical trial for their SCCHN. Participants who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for Overall survival (OS) can be enrolled
Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma

To compare the effect of intraocular pressure control and the incidence of peripheral anterior synechia between CLASS combined with phacoemulsification and CLASS alone in the treatment of primary open-angle glaucoma

Group A: CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification; Group B: simple CO2 Laser-Assisted Sclerectomy Surgery. The patients were followed up for 1 year. The incidence of peripheral anterior synechia and Intraocular pressure changes at 1 day, 1 week, 1 month, 2 months, 3 months, 6 months and 12 months were observed and compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Primary open-angle glaucoma patients with cataract in our Ophthalmic Center;
* Topical use of hypotensive drugs in the treatment of poor or intolerable intraocular pressure control;
* The patients were aged from 50 to 80 years old, regardless of gender;
* Class operation and phacoemulsification were performed;
* Patients are able and willing to comply with the research guidance and may complete all visits required by the research;
* Informed consent has been signed.

Exclusion Criteria:

* Allergic to any perioperative medication in this study;
* History of ocular trauma;
* Any previous intraocular surgery;
* Angle of the chamber was narrow by angle microscopy (Schaffer grade III and below);
* Patients diagnosed as secondary glaucoma;
* Optic atrophy caused by other reasons;
* The serious complications such as posterior capsule rupture and choroidal hemorrhage occurred during the operation;
* Serious complications of eyes occurred after operation;
* The patient's history indicated that he had severe dysfunction of heart, lung, liver and kidney;
* Women in pregnancy, lactation or planned pregnancy;
* The researchers believe that the patient's condition may put the patient at significant risk, and may confuse the research results.
Relation Between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients

Relation between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients


Eligibility Criteria:
Inclusion Criteria:

* Aged between 18 and 80 years, extremes included
* Kidney transplants with or without other transplant organs
* Informed consent
* Stable clinical condition on the basis of a pre-trial physical examination, medical history, and the results of blood biochemistry and haematology tests

Exclusion Criteria:

* Pregnant, lactating females
* Recent (\< 4 weeks) change in antihypertensive drug medication
* Current or recent (\< 2 weeks) acute illness such as infection or bleeding
* Current treatment for malignancy
Fibroid Ablation Study

The primary objective of this study is to establish the effectiveness and confirm the safety of the VizAblate System in ablating symptomatic uterine fibroids.


Eligibility Criteria:
Inclusion Criteria:

* 28 years of age or older
* Regular, consistent menstrual cycles
* History of excessive bleeding
* One Menstrual Pictogram score ≥ 120 during a one-month screening period
* Baseline Uterine Fibroid Symptom \& Quality of Life (UFS-QOL) Symptom Severity Subscale (SSS) score ≥ 20
* Between 1 and 5 Target Fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc
* At least one fibroid must indent the endometrium
* Subject is not at material risk for pregnancy.
* Subject is willing to maintain use or non-use of hormonal contraception
* Subject is willing to have uniform maintenance (use or non-use) of any antifibrinolytic or nonsteroidal anti-inflammatory agents

Exclusion Criteria:

* Subserosal fibroids with bulk symptoms
* Presence of type 0 intracavitary fibroids
* Any Target Fibroid \> 5 cm in maximum diameter with a volume \> 82.4cc
* Any fibroid that obstructs access of the VizAblate probe
* Postmenopausal by history
* Desire for current or future fertility
* Hemoglobin \< 6 g/dl
* Pregnancy
* Evidence of disorders of hemostasis
* Use of Gonadotropin-releasing hormone (GnRH) agonist or implantable or injectable progestin and/or estrogen, Selective Estrogen Receptor Modulators (SERM) or selective progesterone receptor modulator (SPRM)
* Short-term use of hormonal medication for management of bleeding
* Evidence for current cervical dysplasia
* Endometrial hyperplasia
* Confirmed abdominal / pelvic malignancy within the previous five years
* Active pelvic infection
* Clinically significant adenomyosis
* Previous uterine artery embolization. Previous surgical or ablative treatment for fibroids or menorrhagia within previous 12 months
* Current use of anticoagulant therapy
* Need for emergency surgery to treat fibroid symptoms
* Concomitant intrauterine polyps \> 1.0 cm
* Contraindication to MRI
* Renal insufficiency
* Uncontrolled hypertension lasting 2 years or more
* One or more treatable fibroids that are calcified
* Chronic pelvic pain
* Presence of an extrauterine pelvic mass
* Presence of a tubal implant for sterilization
* Previous pelvic irradiation
* Endometrial cavity length \< 4.5 cm
Support To Reunite Involve and Value Each Other

Runaway and homeless youth are at risk for HIV based upon their rates of substance use, particularly injection drug use, unprotected sexual intercourse, multiple partners, and sexually transmitted diseases. Risk increases as the time away from home increases. STRIVE is a family intervention aimed at increasing residential stability, decreasing runaway episodes, and decreasing HIV risk. Families are randomly assigned to a cognitive-behavioral skills-building intervention consisting of five weekly sessions delivered at family homes, or are assigned to standard care. Sessions are aimed at increasing problem solving, role clarity, and positive interactions. It is hypothesized that the intervention will result in improved family dynamics, less runaway behavior, and less risky behavior.


Eligibility Criteria:
Inclusion Criteria:

* Youth: Age 12-17 who ran away or were told to leave home within the past 6 months. Must provide assent and parent/guardian must provide informed consent.
* Parent/guardian: must be parent/guardian of participating youth who ran away. Must provide informed consent.

Exclusion Criteria:

* Youth: total time away from home exceeds 12 months. Obvious cognitive impairment. Sexual or physical abuse from the parent/guardian. Lack of assent/consent.
* Parent/guardian: obvious cognitive impairment. Lack of consent.
Endovascular Treatment of Wide Neck Saccular Cerebral Aneurysms

Intracranial aneurysm (IA) is a cerebrovascular disorder in which the weakness of a cerebral artery wall causes a localized dilation of the blood vessel. Intracranial aneurysm can develop and rupture, and about 85% of spontaneous subarachnoid hemorrhage (SAH) cases are caused by the rupture of Intracerebral aneurysm.

Two treatments are available globally: microsurgical clipping and endovascular treatment.

Endovascular treatment of Intracerebral aneurysms using detachable platinum coils ( was introduced in 1990 by Guido Guglielmi, an Italian neurosurgeon ) of different shapes and sizes are deposited into the aneurysm through a microcatheter, which reduces the blood flow and induces thrombus formation .

Wide neck aneurysm defined by neck diameter greater than 4 mm or dome-to-neck ratio less than 2 Despite advances in endovascular techniques , the treatment of wide-necked aneurysms remains problematic . Endovascular treatment of intracranial aneurysms is associated with lower morbidity and mortality rates and faster recovery compared with traditional microsurgical clipping.

In wide-necked Intracerebral aneurysms, complete coil embolization is often technically difficult owing to the risks of distal coil migration or coil impingement on the parent vessel .

Complete coil embolization using a single microcatheter without a supporting device in cases of wide-necked Intracerebral aneurysm is technically difficult. Total occlusion rates have increased recently as a result of the advancement of supporting devices These may include balloon remodeling, use of three-dimensional (3D) coils (Russian Doll Technique), combined use of stents and coils (Stent assisted coiling), flow diverters, use of intrasaccular flow disruption (like WEB), Double catheter Technique or combined extra- and intrasaccular devices.


Eligibility Criteria:
Inclusion Criteria:

* All patients of spontaneous subarachnoid haemorrhage due to ruptured wide neck saccular cerebral aneurysms
* unruptured Denovo wide neck saccular cerebral aneurysms

Exclusion Criteria:

* other forms of cerebral aneurysms rather than saccular type : fusiform and dissecting aneurysms
* complex aneurysms : giant and thrombosed aneyrsms
* any spontaneous subarachnoid haemorrhage with world fedriation of neurosurgery societies (WFNS) Grade 4\&5
* Any patient unfit for general anesethia or has serious renal impairment
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy
* At least one prior chemotherapy for palliative therapy
* Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria:

* Concurrent administration of any other tumor therapy
* Pregnant or breast feeding
* Serious concomitant disorders
* Inability or unwillingness to take folic acid or vitamin B12 supplementation